Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


Delayed Swiss Exchange  -  11:31:51 2023-01-26 am EST
82.68 CHF   -3.07%
01/25Novartis Files Petition With Supreme Court to Protect Gilenya Patent
01/25NOVARTIS AG : Sell rating from Barclays
01/25Deciphex Limited announced that it has received €14.8 million in funding from a group of investors
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

06/19/2020 | 05:32pm EST
  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made
  • Novartis remains committed to ongoing research and development for COVID-19
  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

Basel, June 19, 2020 - Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19. No safety issues have been reported, and there are no conclusions on efficacy from the study.

Novartis will continue to provide supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met and the medicine is used in accordance with a nationally endorsed treatment protocol. Researchers at Novartis continue to monitor ongoing guidance from health authorities on the further study of HCQ for COVID-19, as well as the decision by the US Food and Drug Administration to stop the emergency use authorization of HCQ for COVID-19 treatment. In addition, ongoing studies involving other Novartis treatments continue, as well as the newly announced support of a potential vaccine. Novartis also continues to collaborate to find answers for COVID-19 through various partnerships with multi-stakeholder external consortia.

Novartis wishes to thank all of the patients, their families, investigators and healthcare professionals who played a vital part in our HCQ clinical trial (CJWT629A12301, NCT04358081) for COVID-19.

More information about the Novartis response to COVID-19 is available on novartis.com/coronavirus.

This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'seek,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products, or regarding our activities and commitments to respond to the COVID-19 pandemic. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that such products will be commercially successful in the future. Nor can there be any guarantee that our activities and commitments to respond to the COVID-19 pandemic will achieve any or all of their intended goals in the expected time frame, or at all. In particular, our expectations regarding such products, activities and commitments could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]

# # #

Novartis Media Relations
E-mail: [email protected]

Anja von Treskow
Novartis Global Media Relations
+41 61 324 2279 (direct)
+41 79 392 8697 (mobile)
[email protected]

Eric Althoff
Novartis US External Communications
+1 646 438 4335
[email protected]

Ryan McBride
Novartis Global Drug Development Communications & Advocacy
+41 61 324 12 88 (direct)
+41 79 156 92 97 (mobile)
[email protected]

Steffen Kurzawa
Sandoz Communications
+49 80244-762590 (direct)
+49 170 901 2622 (mobile)
[email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Pierre-Michel Bringer
Thomas Hungerbuehler
Isabella Zinck
+41 61 324 1065
+41 61 324 8425
+41 61 324 7188
Cory Twining +1 862 778 3258


Novartis AG published this content on 19 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 June 2020 21:31:01 UTC

ę Publicnow 2020
All news about NOVARTIS AG
01/25Novartis Files Petition With Supreme Court to Protect Gilenya Patent
01/25NOVARTIS AG : Sell rating from Barclays
01/25Deciphex Limited announced that it has received €14.8 million in funding from a gr..
01/24Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton...
01/24Europe's revenue growth expected to slow to a crawl in Q4
01/24Sandoz announces agreement to acquire leading antifungal agent Mycamine from Astellas, ..
01/24NOVARTIS AG : Goldman Sachs reiterates its Buy rating
01/23Novartis' Sandoz to Buy Global Rights for Antifungal Medicine Mycamine
01/23Sandoz announces agreement to acquire leading antifungal agent Mycamine« from Astellas,..
01/23Novartis : Sandoz announces agreement to acquire leading antifungal agent Mycam..
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 51 244 M - -
Net income 2022 8 589 M - -
Net Debt 2022 7 406 M - -
P/E ratio 2022 22,1x
Yield 2022 3,72%
Capitalization 193 B 193 B -
EV / Sales 2022 3,91x
EV / Sales 2023 3,88x
Nbr of Employees 108 000
Free-Float 87,1%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 89,72 $
Average target price 95,73 $
Spread / Average Target 6,71%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG2.05%199 399
JOHNSON & JOHNSON-4.72%443 181
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-2.13%275 319